01:21 PM EDT, 05/31/2024 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) was advancing 4% Friday after the drugmaker said a late-stage trial of its candidate, sebetralstat, to treat hereditary angioedema, a swelling disorder, met primary and secondary endpoints.

The median time for patients to begin experiencing a reduction in their swelling was 1.61 hours in people who received 300 milligrams of sebetralstat and 1.79 hours with 600 milligrams, compared with 6.72 hours for the placebo group.

Sebetralstat also showed the same safety profile as a placebo, with no patient withdrawals from the phase 3 trial due to any adverse or treatment-related serious events.

The company presented the data at an industry conference and was published simultaneously in the New England Journal of Medicine.

Price: 11.74, Change: +0.49, Percent Change: +4.36